United Kingdom· GB-APID-39652711000001109
Casirivimab (REGN10933) 120mg/ml solution for infusion 11.1ml vials
A medicinal product containing casirivimab, registered in United Kingdom by University of Oxford.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Casirivimab
- Manufacturer
- University of Oxford
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Casirivimab in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b9310b9f-fc0b-47fd-81a2-c6be99b2ad10 GET /v1/drugs/b9310b9f-fc0b-47fd-81a2-c6be99b2ad10?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "39652711000001109",
"desc": "Casirivimab (REGN10933) 120mg/ml solution for infusion 11.1ml vials (University of Oxford)",
"form": "Solution for infusion",
"vpid": "39657711000001106",
"source": "dmd",
"vtm_id": "1162701003",
"strength": "120 mg",
"substance": "Casirivimab",
"ingredient": "Casirivimab",
"supplier_code": "39658511000001102"
}See everything about casirivimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.